The Lancet Infectious Diseases
Aug 2015 Volume 15 Number 8 p863-986
http://www.thelancet.com/journals/laninf/issue/current

.
Comment
New vaccine strategies to finish polio eradication
Nicholas C Grassly
Published Online: 17 June 2015
Summary
The Global Polio Eradication Initiative (GPEI) currently faces two specific challenges. First, all the cases in the past 9 months caused by ongoing wild-virus transmission were in Afghanistan and Pakistan—Africa has had a remarkable 9 months without detection of the disease. Second, circulating vaccine-derived polioviruses are continuing to cause poliomyelitis in a few countries, a rare outcome associated with continued use of the live-attenuated oral poliovirus vaccine (OPV). In The Lancet Infectious Diseases, the results of two clinical trials of OPV that address these challenges are reported by Fatima Mir and colleagues1 and Concepción Estívariz and colleagues.

Comment
Making mandatory vaccination truly compulsory: well intentioned but ill conceived
Daniel A Salmon, C Raina MacIntyre, Saad B Omer
Summary
The USA, Australia, and about half of European countries have mandatory vaccination requirements.1,2 The experience of the USA and Australia has been well studied. In the USA, vaccine mandates are implemented through requirements for proof of vaccination or exemption at school entry. In Australia, many provinces have school entry requirements and nationally mandated vaccination has traditionally been implemented by denial of childcare benefits to those who refuse vaccines—unless they provide proof of exemptions.

.

Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial
Fatima Mir, Farheen Quadri, Ondrej Mach, Imran Ahmed, Zaid Bhatti, Asia Khan, Najeeb ur Rehman, Elias Durry, Maha Salama, Steven M Oberste, William C Weldon, Roland W Sutter, Anita K M Zaidi

Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial
Concepción F Estívariz, Abhijeet Anand, Howard E Gary Jr, Mahmudur Rahman, Jannatul Islam, Tajul I Bari, Steven G F Wassilak, Susan Y Chu, William C Weldon, Mark A Pallansch, James D Heffelfinger, Stephen P Luby, Khalequ Zaman

Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study
Danielle V Clark, Hannah Kibuuka, Monica Millard, Salim Wakabi, Luswa Lukwago, Alison Taylor, Michael A Eller, Leigh Anne Eller, Nelson L Michael, Anna N Honko, Gene G Olinger Jr, Randal J Schoepp, Matthew J Hepburn, Lisa E Hensley, Merlin L Robb
905